# Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

> **NCT04634799** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Northwestern University** · enrollment: 9 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** TM5614
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04634799
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-01-08
- **Primary completion:** 2025-04-23
- **Final completion:** 2025-05-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Enrollment challenges; new batch of drug is being manufactured and there may be additional impetus to reactivate after the analogous Phase 2 study in Japan is completed and those results are made available
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04634799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04634799, "Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04634799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*